Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
RESEARCH TOOLSreports
Hikma Pharmaceuticals (HIK) Share Price & Analysis
22 Followers
HIK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,623.61p - 2,179.68p
Previous Close1,839p
Volume55.37K
Average Volume (3M)642.98K
Market Cap
£4.08B
Enterprise Value4.87B
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$1.28B
Price to Earnings (P/E)26.6
Beta0.86
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.04%
Share Statistics
EPS (TTM)0.69
Shares Outstanding221,885,259
10 Day Avg. Volume515,666
30 Day Avg. Volume642,981
Standard Deviation0.11
R-Squared0.00655
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.73
Price to Sales (P/S)410.59
Price to Cash Flow (P/CF)11.80
P/FCF Ratio18.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.94
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2,145.00pPrice Target Upside17.76% Upside
Rating ConsensusHold
Number of Analyst Covering5
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals Grants Executive Share Award
Options Prices
Currently, No data available
---
Ownership Overview
8.98% Insiders
7.70% Mutual Funds
8.28% Other Institutional Investors
75.04% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest share price was 1623.61p and its highest was 2179.68p in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Currently, no data Available
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Aug 08, 2024 which is in 106 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Feb 22, 2024. The company reported 0.214p earnings per share for the quarter, beating the consensus estimate of N/A by 0.214p.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC does not currently pay dividends.
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 221,885,250 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of 0.214p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.28%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:HIK
---
Hikma Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
2,145.00p (17.76% Upside)
2,145.00p (17.76% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth £374.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.02%
12-Months-Change
Fundamentals
Return on Equity
8.76%
Trailing 12-Months
Asset Growth
-1.23%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.
---
HIK Stock 12 Months Forecast
Average Price Target
2,145.00p
▲(17.76% Upside)
Technical Analysis
Best Analysts Covering HIK
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+6.27%
reiterated a buy rating 5 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +6.27% per trade.
---